The US health regulator has provided its approval to Lupin for marketing its Balasalazide Disodium tablets that are used to treat uclerative colitis, in the American market.

Lupin has said in a BSE filing that the company has received tentative approval to market its Balasalazide Disodium tablets 1.1 gm from the United States Food and Drug Administration (USFDA).

It added that the company’s product is a generic version of Salix Pharmaceuticals Inc’s Giazo tablets in the same strength.

Read EquityPandit’s Technical Analysis on Nifty Pharma